How to Read an S-1 Filing: 7 Sections That Actually Matter (2026 Guide)

82 US IPOs had priced by mid-2026, per Renaissance Capital, and every single one of them filed an S-1 that most retail investors never open past page three. That's the short answer. The longer answer is more interesting.

I've read a lot of S-1s — as a founder prepping a company for the process, and as an investor trying to figure out whether a filing is worth chasing on the open market. The document is 150-300 pages long by design; most of it is legal boilerplate written to survive litigation, not to inform you. But seven sections consistently carry the entire investment thesis. Skip the rest, read those seven, and you'll know more than 90% of people trading the stock on day one.

How to Read an S-1 Filing: Start With the Prospectus Summary

How to read an S-1 filing starts with the Prospectus Summary, a 5-10 page condensed version of the entire document that appears first and is written to be skimmed. It contains the company's self-selected highlight numbers — revenue, growth rate, customer count, gross margin — chosen specifically because they're the most flattering figures in the filing. Treat it as a marketing abstract, not neutral analysis, but use it as a map: whatever metric the company leads with in the summary is the metric it's most confident will hold up under scrutiny in the full document.

Cerebras Systems filed its S-1 on April 17, 2026, targeting a Nasdaq listing at a $22-25B valuation. Its summary led with $510M in 2025 revenue, up 76% year-over-year from a roughly $272M annualized run rate in the first half of 2024, and a $10B multi-year contract with OpenAI. That's a textbook summary: the two strongest numbers in the entire filing, placed on page one, because everything after page one gets progressively more qualified.

Risk Factors: The Section Lawyers Write, But Founders Should Read Closest

Risk Factors runs 20-40 pages and is legally required to disclose every material risk the company's counsel is aware of — not because the company wants to warn you, but because omitting a known risk exposes the company to shareholder litigation after the IPO. That legal incentive is exactly why this section is more honest than the Prospectus Summary. A generic risk ("we operate in a competitive market") tells you nothing. A specific risk ("we derive approximately 40% of revenue from a single customer contract expiring in 2027") tells you the single biggest thing that could break the thesis.

Concentration risk is the pattern to hunt for first. Cerebras disclosed a $10B contract with OpenAI as a headline win — but a contract that large relative to $510M in trailing revenue also means a meaningful chunk of forward revenue depends on one counterparty's continued spending. That's not a red flag on its own; it's a number you need before you can size the position. Read risk factors in order of specificity, not in the order they're printed — the boilerplate ones ("general economic conditions could harm our business") are filler; the oddly precise ones are the real disclosure.

MD&A and Financial Statements: Where the Numbers Get Real

Management's Discussion and Analysis (MD&A) is the section where the business narrative meets the audited numbers, and it's where deceleration shows up months before it hits headlines. If revenue grew 76% year-over-year but the most recent quarter grew only 40% sequentially annualized, MD&A is where management has to explain the gap — and the explanation, or its absence, tells you whether growth is decelerating structurally or just seasonally.

Structure and page-length ranges blended from EquityZen, Crunchbase News, and MicroVentures S-1 explainers, cross-checked against the actual Cerebras, Klarna, and Chime 2026 S-1 filings. Page counts vary by company complexity.

Financial Statement Footnotes: Where the Accounting Choices Live

Most readers stop at the three primary statements — income statement, balance sheet, cash flow statement — and skip the footnotes entirely. That's a mistake, because the footnotes are where stock-based compensation expense, revenue recognition policy, and any related-party transactions get disclosed in detail the summary tables don't show. A company can post an impressive top-line revenue number while burying a stock-based comp expense in the footnotes that's large enough to erase most of the reported operating margin.

Three fiscal years of audited financials are required, which lets you compute your own year-over-year growth rate rather than trusting the one management chose to highlight. Klarna's 2026 S-1 targeted a $15-20B valuation, a significant discount to its 2021 peak of $46B — the kind of gap that only becomes fully legible once you compare multiple years of revenue and take-rate trends side by side in the financial statements, not the summary paragraph.

Use of Proceeds, Dilution, and Beneficial Ownership: The Insider Signal

Use of Proceeds is short — often one or two pages — but tells you whether new capital funds growth or funds an exit ramp for insiders. Language like "general corporate purposes, including working capital" paired with a large "selling stockholders" allocation means existing investors are cashing out at the IPO price, not that the company itself is raising growth capital. That's common and not automatically bad, but it changes what the IPO is actually for.

Dilution shows the price gap between what early investors paid per share years ago and what new public investors pay at the offering price — commonly 60-90% for high-growth tech IPOs. Beneficial Ownership then shows who controls votes after the IPO: founders retaining supervoting shares, or a VC fund holding a board seat and a lockup-expiration date that will flood the float with new supply 90-180 days after listing. Chime targeted roughly $25B in its 2026 IPO with 22M+ accounts and 2024 profitability — the ownership table is where you'd see exactly how much of that value still sits with founders versus the venture funds that backed it through years of unprofitability.

Track how these newly public companies trade against their S-1 numbers on our Tech IPO dashboard, which follows post-listing performance against the growth and margin figures disclosed at filing.

Comparing Multiple S-1s: Cerebras, Klarna, and Chime Side by Side

Reading one S-1 in isolation only gets you so far — the real signal shows up when you compare filings from the same IPO window against each other. All three of the highest-profile 2026 filers took different paths to the same market, and the differences show up exactly in the seven sections above, not in the press coverage.

Figures blended from company S-1 filings, Renaissance Capital, and Crunchbase News 2026 IPO coverage. Valuation targets are pre-pricing estimates and may shift materially before listing.

Notice the pattern: Cerebras is selling growth and a marquee contract, Klarna is selling a profitability turnaround at a valuation discount, and Chime is selling scale plus profitability together. Three different pitches, and each one tells you exactly which S-1 section to scrutinize hardest — concentration risk for Cerebras, margin durability for Klarna, unit economics for Chime.

How Founders Should Prepare Before Filing an S-1

For founders on the other side of this document, the S-1 process forces a level of financial discipline most late-stage private companies haven't had to build yet — three years of audited statements, disclosure controls, and a legal review of every material risk. Start building GAAP-clean financials 18-24 months before a target filing date, not six. The single most common delay I've seen in real IPO timelines isn't investor demand — it's the finance team needing two to three extra quarters to get historical statements audit-ready.

The Prospectus Summary is also worth drafting early and honestly, internally, well before counsel touches it — if the two or three numbers you'd lead with today wouldn't survive being placed on page one of a legal document, that's a signal to fix the underlying metric, not the messaging, before a banker ever sees the deck.